Hepatocellular Carcinoma Epithelial Cell HepG2 Transfection Kit

Modes of administration

Reagent exhibits at least 90% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Description

HepG2, an epithelial cell line derived from a 15-year-old male patient with hepatocellular carcinoma, is a well-known and valuable tool in the study of liver cancer. The disease is highly aggressive and has limited treatment options, making HepG2's sensitivity to a variety of chemotherapeutic agents such as cisplatin and doxorubicin crucial for the toxicological evaluation of novel drug combinations. With a model chromosome number of 55, HepG2 secretes several major plasma proteins and is responsive to human growth hormone stimulation. It has been grown successfully in large-scale cultivation systems, although it has also been shown to be resistant to G418. HepG2's significance extends beyond toxicological assessments, as researchers use its derivatives to study liver metabolism, xenobiotic toxicity, hepatocarcinogenesis, drug targeting, and antigenotoxic and cogenotoxic agents. Additionally, the cell line is commonly employed in bio-artificial liver device trials. HepG2's importance in biomedical research cannot be overstated, and CD BioSciences provides highly efficient transfection reagent kits to support its use in various studies.